Research library

Evidence first. Claims second.

Research overviews for the compounds people actually search for, with clear separation between human trials, preclinical work, mechanistic interest, and unanswered questions.

Research methodVisual note

Every note starts with the evidence category.

Human trials, official regulatory status, preclinical models, and batch-documentation questions are separated before any product context appears.

Incretin pathway mapVisual note

GLP-1 status map

GLP-1, GIP, and glucagon-axis research should be read by evidence stage: approved labels, human trials, and investigational programs are separate categories.

Repair-biology modelVisual note

Repair-biology evidence map

Regenerative peptide literature often centers on matrix remodeling, fibroblast signaling, migration, and preclinical wound-healing models.

Cellular energy mapVisual note

Cellular-energy context

NAD+ research connects redox biology, mitochondrial function, and repair signaling, but biomarker movement is not the same as proven outcome benefit.

Topic cluster

Incretin timeline

Semaglutide, tirzepatide, retatrutide, FDA milestones, and public-policy context.

Topic cluster

Human trial anchors

Pages that separate randomized human outcomes from mechanistic explanation.

Topic cluster

Preclinical caution

Repair, tanning, and regenerative compounds where claims often outrun evidence.

SemaglutideField note 01

Semaglutide research: what the current human data actually shows.

Semaglutide has one of the strongest modern human evidence bases in this catalog class, with randomized trials showing substantial weight-loss effects and cardiovascular outcome data in selected populations.

Answers: What is semaglutide being studied for in the strongest published human data?

Read research note

TirzepatideField note 02

Tirzepatide research: why the dual-incretin data changed the conversation.

Tirzepatide brought unusually strong weight-loss data into the incretin conversation, with large human trials pushing outcome magnitude beyond what earlier single-pathway agents had established.

Answers: Why do researchers pay so much attention to tirzepatide right now?

Read research note

RetatrutideField note 03

Retatrutide research: early human results, bigger upside, and bigger uncertainty.

Retatrutide produced striking phase 2 obesity results, but the evidence base is still earlier and less mature than semaglutide or tirzepatide, so hype should not be confused with confirmation.

Answers: What do we actually know about retatrutide from human studies so far?

Read research note

GLP-1 timelineField note 04

GLP-1 regulatory timeline: approvals, retatrutide status, and why the search demand keeps rising.

GLP-1 search demand is no longer just a product trend. It sits at the intersection of FDA approvals, phase 3 obesity research, insurance policy, podcast-driven public attention, and safety monitoring.

Answers: What is the current FDA and research status of semaglutide, tirzepatide, and retatrutide?

Read research note

GHK-CuField note 05

GHK-Cu research: where the evidence is interesting and where it is still mostly preclinical.

GHK-Cu has a long history of regenerative and wound-healing interest, but much of the excitement still comes from preclinical and mechanistic literature rather than large modern human trials.

Answers: What does the literature really support for GHK-Cu right now?

Read research note

BPC-157Field note 06

BPC-157 research: wound-healing interest, animal data, and the human evidence gap.

BPC-157 has a large wound-healing and cytoprotection literature footprint, but most of the persuasive evidence remains preclinical rather than large, modern human trials.

Answers: What is the strongest evidence category for BPC-157 right now?

Read research note

TB-500 / Thymosin Beta-4Field note 07

TB-500 research: thymosin beta-4 biology and tissue-repair questions.

TB-500 is discussed as a synthetic thymosin beta-4-related research peptide, but the strongest literature is better understood through thymosin beta-4 biology than finished human outcomes.

Answers: What is TB-500 research actually based on?

Read research note

NAD+Field note 08

NAD+ research: human precursor trials, aging biology, and realistic expectations.

NAD+ biology is central to metabolism and aging research, but human trial interpretation needs care because precursor supplementation, NADH, and NAD+ itself are often blended together online.

Answers: What do human studies say about NAD+ and NAD+-boosting compounds?

Read research note

Melanotan IIField note 09

Melanotan II research: melanocortin biology, pigmentation, and safety questions.

Melanotan II sits in the melanocortin receptor literature, with research touching pigmentation and sexual-function pathways, but safety concerns and online misuse make careful framing essential.

Answers: What is Melanotan II research actually about?

Read research note